Spark Investment Management LLC acquired a new stake in shares of Urogen Pharma Ltd (NASDAQ:URGN) during the second quarter, Holdings Channel reports. The firm acquired 47,400 shares of the company’s stock, valued at approximately $856,000.

Urogen Pharma Ltd (NASDAQ:URGN) opened at 17.67 on Friday. The stock’s 50 day moving average price is $18.03 and its 200 day moving average price is $17.57. The company’s market capitalization is $40.73 million. Urogen Pharma Ltd has a 12 month low of $11.09 and a 12 month high of $20.02.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/spark-investment-management-llc-acquires-new-position-in-urogen-pharma-ltd-urgn/1472344.html.

Several equities analysts have recently commented on the company. Zacks Investment Research upgraded Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Wednesday, August 2nd. Raymond James Financial, Inc. assumed coverage on Urogen Pharma in a research report on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price objective on the stock. Oppenheimer Holdings, Inc. assumed coverage on Urogen Pharma in a research report on Tuesday, May 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Jefferies Group LLC assumed coverage on Urogen Pharma in a research report on Tuesday, May 30th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Cowen and Company assumed coverage on Urogen Pharma in a research report on Tuesday, May 30th. They set an “outperform” rating on the stock. Five research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $26.00.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma Ltd (NASDAQ:URGN).

Receive News & Ratings for Urogen Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.